Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2013 and its Form 10-Q for the quarter ended March 31, 2014.  The reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Contacts Sanofi:Media Relations

Investor Relations Jack Cox

Sebastien MartelTel: +33 (0) 1 53 77 94 74

Tel: +33 (0)1 53 77 45 45Mobile: +33 (0) 6 78 52 05 36

E-mail: IR@sanofi.com E-mail: Jack.Cox@sanofi.com <
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... Fla. , March 25, 2015  Point-of-Care ... and management consulting firm, has launched the ePrescribing ... to simplify tracking of ePrescribing regulatory requirements in ... "The ePrescribing regulatory landscape continues to change rapidly, ... deliver what the industry, and ultimately patients, need," ...
(Date:3/25/2015)... Having added two International locations in Brisbane and ... Global proudly announced recently the organization’s expansion into Poland. ... in the United States, is one of the largest ... real estate. , Saltwood International is the ... advises occupiers of office space, ensuring that its corporate ...
(Date:3/25/2015)... LOUIS and the HAGUE, Netherlands ... of two-year results of LES Stimulation therapy for chronic ... the journal Surgery [ Surgery . ... efficacy of its minimally-invasive therapy. The ... average duration of 11 years and taking prescribed daily ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2International Organization Expands its Global Reach to Warsaw, Poland 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... EST, WALTHAM, Mass., Jan. 31 Repligen Corporation,(Nasdaq: ... and Chief,Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 11:00 a.m. EST, to report,third quarter fiscal year ... the Company., This call is being webcast by ...
... siRNA, to Identify 273 Human Proteins Needed for Reproduction of ... ... AIDS, WALTHAM, Mass., Jan. 31 Thermo Fisher,Scientific Inc., the ... has enabled a groundbreaking study,at Harvard Medical School in Boston, which ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
Cached Biology Technology:Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 3Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 2Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 3Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 4Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 5Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... League Baseball pitchers indicates that the height of the pitchers ... lead to potential injuries because of stress on the shoulder ... William Raasch, M.D., associate professor of orthopaedic surgery at the ... head team physician for the Milwaukee Brewers. Major League Baseball ...
... Walker is taking on one of the biggest killers in ... battle to save lives, especially the lives of children., With ... Walker will lead a research team studying how insecticide-treated bed ... causes the deadly disease, as well as the mosquito that ...
... many researchers have believed women choose partners based ... a new study from The University of Texas ... by their own attractiveness. David Buss, psychology ... in Attractive Women Want it All: Good Genes, ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Netting mosquitoes to prevent malaria 2Do attractive women want it all? 2
Special grade: for electrophoresis...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
Contact us for more information...
Biology Products: